Retraction notice to "In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma" [Life Sciences 285 (2021) 119961].

Mamdouh AM; Khodeer DM; Tantawy MA; Moustafa YM

doi:10.1016/j.lfs.2026.124268

← 뒤로

Retraction notice to "In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma" [Life Sciences 285 (2021) 119961].

Life sciences 2026 Vol.390() p. 124268

Mamdouh AM, Khodeer DM, Tantawy MA, Moustafa YM

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Mamdouh AM, Khodeer DM, et al. (2026). Retraction notice to "In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma" [Life Sciences 285 (2021) 119961].. Life sciences, 390, 124268. https://doi.org/10.1016/j.lfs.2026.124268

MLA Mamdouh AM, et al.. "Retraction notice to "In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma" [Life Sciences 285 (2021) 119961].." Life sciences, vol. 390, 2026, pp. 124268.

PMID 41708456

DOI 10.1016/j.lfs.2026.124268